Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

Cell. 2017 Feb 9;168(4):707-723. doi: 10.1016/j.cell.2017.01.017.

Authors

Padmanee Sharma¹, Siwen Hu-Lieskovan², Jennifer A Wargo³, Antoni Ribas⁴

Affiliations

¹ Department of Genitourinary Medical Oncology and Immunology,The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: padsharma@mdanderson.org.
² Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles and the Jonsson Comprehensive Cancer Center, Los Angeles, CA 90095, USA.
³ Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
⁴ Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles and the Jonsson Comprehensive Cancer Center, Los Angeles, CA 90095, USA. Electronic address: aribas@mednet.ucla.edu.

Abstract

Cancer immunotherapy can induce long lasting responses in patients with metastatic cancers of a wide range of histologies. Broadening the clinical applicability of these treatments requires an improved understanding of the mechanisms limiting cancer immunotherapy. The interactions between the immune system and cancer cells are continuous, dynamic, and evolving from the initial establishment of a cancer cell to the development of metastatic disease, which is dependent on immune evasion. As the molecular mechanisms of resistance to immunotherapy are elucidated, actionable strategies to prevent or treat them may be derived to improve clinical outcomes for patients.

Keywords: T cells; immunotherapy; resistance mechanisms.

Publication types

Review
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Drug Therapy, Combination
Humans
Immunotherapy*
Molecular Targeted Therapy
Neoplasms / immunology*
Neoplasms / therapy*
T-Lymphocytes / immunology

Abstract

Publication types

MeSH terms

Grants and funding